PDCD1 and cancer: It has been proposed that an IFN-γ score, calculated from the level of expression of different IFN-γ-induced genes including IRF1, can be used as a prognostic marker to determine the potential for anti-PD-1/PD-L1 therapy for some cancer patients [31].